Metraipolis › archive › dc_41b74587dfca

Real-world efficacy and safety of golidocitinib in 3 patients with relapsed/refractory peripheral T-cell lymphoma — Europe PMC PMID:42638677

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42638677
DOI: 10.3389/fonc.2026.1891177
License (as archived): solo-consultazione
Archived: 2026-10-16T21:56:14.003Z
SHA-256 of the archived text: 26e46187c214d07707dda7782c9b0d6210e0fea3297d70d2ba068b7cbdd388fc
Stable URL of this page: https://metraipolis.com/documento/dc_41b74587dfca

How to cite

Real-world efficacy and safety of golidocitinib in 3 patients with relapsed/refractory peripheral T-cell lymphoma — Europe PMC PMID:42638677 — Europe PMC (en), https://europepmc.org/article/MED/42638677 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_41b74587dfca (Metraipolis archive dc_41b74587dfca, sha256 26e46187c214d07707dda7782c9b0d6210e0fea3297d70d2ba068b7cbdd388fc)

BibTeX

@misc{dc41b74587dfca,
  title = {Real-world efficacy and safety of golidocitinib in 3 patients with relapsed/refractory peripheral T-cell lymphoma — Europe PMC PMID:42638677},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42638677},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_41b74587dfca; sha256 26e46187c214d07707dda7782c9b0d6210e0fea3297d70d2ba068b7cbdd388fc},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42638677. Agents can read the archived copy with the MCP tool read_document.